Keytruda + chemo reduces risk of death by one-third vs. chemo as first-line treatment for persistent, recurrent, or metastatic cervical cancer

Results from the phase III KEYNOTE-826 trial demonstrate that Keytruda (pembrolizumab) plus chemotherapy with or without bevacizumab improved disease outcomes when compared to chemotherapy with or without bevacizumab as a first-line treatment of persistent, recurrent, or metastatic cervical cancer.